Download to see the full press release

ThromboGenics To Present at Key Investor Meetings
4 Drug Candidates: Novel Disease Modifying Treatments for Diabetic Eye Disease,
1 Drug Candidate: Innovative Orphan Drug for Treatment of Pediatric Cancer
Leuven, 24 March 2016 – ThromboGenics NV (Euronext Brussels: THR), an integrated
biopharmaceutical company focused on developing and commercializing innovative treatments for
back of the eye disease, today announced that it will be presenting at several key investor meetings
over the next few weeks and months.







Kempen & Co 9th European Healthcare & Life Sciences Conference on April 6 – 7, 2016 in
Amsterdam
Invest Securities 10th European Smallcap Event on April 11 – 12, 2016 in Paris
European Mid Small Cap Forum on May 18, 2016 in London
ING Belgian Day on June 7 – 8, 2016 in New York City
Jefferies 2016 Healthcare Conference on June 7 – 10, 2016 in New York City
Société Générale Healthcare & Biotechnology Conference on June 28, 2016 in Paris
European Mid Small Cap Forum on June 29 – 30, 2016 in Zurich
The announced roadshow plans follow the Company’s introduction of its new drug development
pipeline first presented during last Friday’s ThromboGenics Research & Development Investor
Meeting in London.
Over the past 18 months, ThromboGenics has developed a world class pipeline of disease modifying
drug candidates for the treatment of diabetic eye disease. The pipeline consists of THR-409
(ocriplasmin), THR-317 (anti-PlGF), THR-149 (plasma kallikrein inhibitor), which has resulted from a
research collaboration with Bicycle Therapeutics, and THR-687 (integrin receptor antagonist), which
was recently in-licensed from Galapagos. With that, ThromboGenics will initiate several new clinical
trials over the next 3-4 years, starting in 2016.
Next to its ambitious plans in ophthalmology, ThromboGenics is also progressing its commitments in
oncology via its spin out Oncurious nv, an emerging oncology company focused on the development
of innovative orphan drugs for the treatment of pediatric tumors. Last week’s announcement of the
Oncurious partnership with NMTRC in the US, is a last step in the preparative work before initiating a
Phase I/IIa clinical program with TB-403 for the treatment of medulloblastoma, a rare, lifethreatening pediatric cancer. Further announcements are awaited.
Ends
For further information please contact:
ThromboGenics
Wouter Piepers,
Global Head of Corporate Communications & IR
+32 16 75 13 10 / +32 478 33 56 32
[email protected]
Citigate Dewe Rogerson
Sylvie Berrebi, David Dible
Tel: +44 20 7282 2867 / +44 20 7282 1052
[email protected]
About ThromboGenics
ThromboGenics is an integrated biopharmaceutical company focused on developing and
commercializing innovative treatments for back of the eye disease, with a focus on diabetic eye
disease.
Diabetic retinopathy (DR) and diabetic macular edema (DME) are the fastest growing segments of
the overall ophthalmology market, which is forecast to increase in value from an estimated $1.6
billion in 2015 to $4.2 billion in 2023, or a 16% CAGR.
ThromboGenics pioneered the new drug category of pharmacological vitreolysis with Jetrea®
(ocriplasmin). Jetrea® is now approved for the treatment of vitreomacular traction in over 54
countries worldwide. Alcon, a division of Novartis, commercializes Jetrea® outside the United States.
Recently, ThromboGenics initiated a Phase II clinical trial to assess ocriplasmin as a potential treatment
for diabetic retinopathy.
ThromboGenics is headquartered in Leuven, Belgium, and is listed on the NYSE Euronext Brussels
exchange under the symbol THR. More information is available at www.thrombogenics.com
Important information about forward-looking statements
Certain statements in this press release may be considered “forward-looking”. Such forward-looking
statements are based on current expectations, and, accordingly, entail and are influenced by various
risks and uncertainties.
The Company therefore cannot provide any assurance that such forward-looking statements will
materialize and does not assume an obligation to update or revise any forward-looking statement,
whether as a result of new information, future events or any other reason. Additional information
concerning risks and uncertainties affecting the business and other factors that could cause actual
results to differ materially from any forward-looking statement is contained in the Company’s Annual
Report.
This press release does not constitute an offer or invitation for the sale or purchase of securities or
assets of ThromboGenics in any jurisdiction. No securities of ThromboGenics may be offered or sold
within the United States without registration under the U.S. Securities Act of 1933, as amended, or in
compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities
laws.